Review Article

Safety, strength and simplicity of efavirenz in pregnancy

Prinitha Pillay, Vivian Black
Southern African Journal of HIV Medicine | Vol 13, No 1 | a157 | DOI: https://doi.org/10.4102/sajhivmed.v13i1.157 | © 2012 Prinitha Pillay, Vivian Black | This work is licensed under CC Attribution 4.0
Submitted: 15 December 2012 | Published: 13 March 2012

About the author(s)

Prinitha Pillay, Wits Reproductive Health and HIV Institute (WRHI), University of the Witwatersrand, Johannesburg, South Africa
Vivian Black, Wits Reproductive Health and HIV Institute (WRHI), University of the Witwatersrand, Johannesburg, South Africa


Share this article

Bookmark and Share

Abstract

The WHO recommends starting lifelong ART for all pregnant women with a CD4 count at or below 350 cells/mm³, which recognises the important component of ‘when to start’ and the role that timing of initiation plays in reducing mortality and disease progression. The data on ‘what to start’ are conflicting, and options for resource-limited settings are limited. The choice of an ART regimen for pregnant women is complicated by the need to take into account the health and safety of both the mother and baby. Particularly contentious is whether to use a nevirapine- (NVP) or efavirenz- (EFV) based regimen. This review presents the latest evidence on the safety and efficacy of EFV and NVP in pregnancy and offers recommendations for improving maternal and child health outcomes and avoid mother-to-child transmission as South Africa moves toward turning back the tide on its HIV epidemic.

Keywords

Efavirenz; Pregnancy; PMTCT; Option B

Metrics

Total abstract views: 2738
Total article views: 6116

 

Crossref Citations

1. The effects of in utero exposure to antiretroviral therapy (ART) on the language abilities of HIV exposed uninfected infants
Stevens Tarryn, Schwartz Sheree, Mupawose Anniah, Moonsamy Sharon, Black Vivian
Journal of AIDS and HIV Research  vol: 9  issue: 8  first page: 164  year: 2017  
doi: 10.5897/JAHR2017.0428